Pharmafile Logo

Claire Long

- PMLiVE

Trust and trends – proactive protection

To thrive in today’s communication ecosystem, we must tailor our messaging rationally and emotionally

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

More than seven million people in the US are affected by the neurodegenerative disease

- PMLiVE

BMS granted FDA priority review for Breyanzi in marginal zone lymphoma

The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases

- PMLiVE

Improving transparency and traceability within the supply chain’s first mile

How manufacturers can implement processes to help improve this critical part of the supply chain

- PMLiVE

Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

Treatment options following disease progression have previously been limited for many patients

- PMLiVE

FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU

Phenylketonuria affects one in every 13,500 to 19,000 newborns in the US

- PMLiVE

Motivating low-performance teams

Why some teams act in the same way as organisms that are metabolically impaired

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

- PMLiVE

Celebrating the Cannes Lions International Festival of Creativity

Cannes’ most forward-looking conversations weren’t about pharma – but pharma should have been listening

New team members

Cuttsy+Cuttsy welcomes new team members

Cuttsy+Cuttsy is excited to announce the addition of three talented professionals to the team: Flo, an enthusiastic Account Executive; Vicki, a creative Graphic Designer; and Jo, a detail-driven Artworker

Cuttsy + Cuttsy

Unlocking the future of Learning

By Potter Li and Aaron Fletcher

Amiculum

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links